ArticleDiscover oncology2025
Charting the growth of programmed cell death studies in uveal melanoma: a bibliometric evidence.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUveal melanoma is a malignant intraocular tumor with a high propensity for metastasis, and the significance of programmed cell death (PCD) in this disease has attracted growing attention in recent decades. However, few studies have systematically investigated the global publication trends, collaboration networks, and thematic focus areas in this domain. The current study utilized a bibliometric approach to examine how PCD research in uveal melanoma has evolved from 1999 to 2024, highlighting key contributors, citation patterns, and emerging research topics.
methodsData were collected from the Web of Science Core Collection (WoSCC) for publications dated January 1, 1999-December 31, 2024. We restricted our search to original articles and reviews in English, employing a comprehensive keyword strategy to identify publications specifically addressing PCD mechanisms-such as apoptosis, autophagy, and ferroptosis-in the context of uveal melanoma. After removing duplicates and screening for relevance, 536 publications were included. WoSCC was selected for its standardized indexing and cited-reference data; potential omissions from Scopus, PubMed, or Embase are addressed in Limitations. Bibliometric indicators, including annual output, institutional productivity, citation counts, and keyword co-occurrence, were analyzed using R-bibliometrix and VOSviewer. Data were last retrieved on May 1, 2025; analyses were restricted to the WoSCC 'Publication Year' 1999-2024 to avoid post-hoc reassignment. References published in 2025 are cited only for context and were not counted in the bibliometric dataset.
resultsIn total, 536 articles in 242 distinct sources were identified, reflecting an annual growth rate of 11.05%. The United States and China emerged as the leading producers of relevant publications, exhibiting robust and often international collaborative networks. Top institutions included major Chinese universities (e.g., Sun Yat-sen University and Shanghai Jiao Tong University) and renowned Western research centers such as Harvard University and Leiden University, many of which formed high-density clusters in collaboration maps. Investigative Ophthalmology & Visual Science was the most prolific journal in this area, while Cancer Research and Nature ranked among the top in local citations. Keyword co-occurrence analysis revealed an evolving focus over time-from foundational topics like apoptosis and tumor proliferation to more recent interests in ferroptosis, immunotherapy, and metastatic pathways. These findings suggest that PCD research in uveal melanoma has matured into a dynamic, multidisciplinary field that intersects with precision oncology and immuno-oncology.
conclusionThis bibliometric study established a view of PCD research trends in uveal melanoma, demonstrating the field's rapid expansion, strong international collaborations, and an increasing emphasis on emerging cell-death pathways. These results underscore that deeper mechanistic insights into PCD processes have the potential to inform more effective therapies and prognostic tools, particularly in light of the limited treatment options once metastatic disease occurs. Early integration of PCD-focused hypotheses may support precision-medicine study design; however, bibliometrics cannot establish treatment benefit, and clinical trials are required to determine whether PCD-targeted strategies improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.